INBRAIN Neuroelectronics , a company dedicated to the development of graphene-based neural technologies for BCI therapeutic interfaces (BCI-Tx), announced the signing of a collaboration agreement with Mayo Clinic for the exchange of technical knowledge. The objective of this initiative is to accelerate the development and commercialization of INBRAIN’s precision BCI-Tx technology for patients with neurological disorders.
As part of the collaboration, INBRAIN and Mayo Clinic experts will work together on a non-exclusive expertise exchange to conduct a practical evaluation of INBRAIN’s developmental BCI-Tx platform in clinical trials, with the goal of accelerating the generation of high-quality clinical evidence.
“Our goal is to maximize the unique capabilities of graphene and artificial intelligence to generate true value for both patients and medical teams,” said Carolina Aguilar, CEO and co-founder of INBRAIN Neuroelectronics. “With the clinical expertise of Mayo Clinic, and alongside other leading centers in the United States and Europe, we seek to validate our platform in real-world settings, accelerate clinical evidence, and responsibly advance patient-centered BCI therapies.”
Also Read: Inizio names Ryan Quigley as new CEO to drive growth
INBRAIN also announces the creation of a US subsidiary to collaborate with leading US academic centers, with locations to be opened in Boston and the West Coast, while maintaining its headquarters and R&D department in Barcelona, Spain. The initial Boston office will serve as the hub for US clinical trials and lay the groundwork for the commercialization and therapeutic expansion of its BCI-Tx beyond Parkinson’s disease. INBRAIN is also developing scalable manufacturing processes for its BCI platform to enable broader clinical and commercial adoption worldwide.
INBRAIN has raised $124 million in funding to date from an international consortium of medtech and deeptech investors, including, in alphabetical order, Aliath Bioventures, Asabys Partners, CDTI, the Generalitat de Catalunya (Avançsa and ICF), FondICO, Graybella Capital, IMECXpand, Mayo Clinic, the European Innovation Council, Truventuro, and Vsquared Ventures.
Mayo Clinic has a financial interest in the technology mentioned in this press release. Mayo Clinic will use the proceeds it receives to fund its nonprofit mission of patient care, education, and research.
Source: Businesswire